drugset
drugset / Trial / NCT00180921

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

NCT00180921 ↗

Phase 2 Unknown 30 enrolled Gustave Roussy, Cancer Campus, Grand Paris
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II study of imatinib (Glivec) administered as a daily oral treatment in patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck overexpressing KIT.

Timeline

Start
2004-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — Oral

Indications

adenoid cystic carcinoma head and neck cancer